In 1995, the pooled results of two phase III National Institute of Neurological Disorders and Stroke (NINDS) tissue plasminogen activator trials, demonstrated that IV tPA in acute ischemic stroke was safe and effective when given within 3 hours from symptoms onset avoiding patients’ death or functionally dependent of one out of seven patients treated [4]. The gene discussed is PLAT; the disease is stroke disorder.